Compare MDBH & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | PRPO |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 32.4M |
| IPO Year | 2023 | N/A |
| Metric | MDBH | PRPO |
|---|---|---|
| Price | $3.63 | $23.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 14.7K | 7.7K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | $1,250,398.00 | ★ $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.75 | ★ N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $3.11 | $3.90 |
| 52 Week High | $7.98 | $28.50 |
| Indicator | MDBH | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 53.11 | 53.28 |
| Support Level | $3.11 | $22.40 |
| Resistance Level | $3.69 | $24.92 |
| Average True Range (ATR) | 0.19 | 1.26 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 70.69 | 61.96 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.